CLLS - Cellectis Announces the execution of the Subsequent Investment Agreement with AstraZeneca | Benzinga
- Execution of binding subsequent investment agreement regarding contemplated additional equity investment of $140M by AstraZeneca, previously announced on November 1, 2023.
- Extraordinary shareholders' meeting of Cellectis to be held on or around December 22, 2023 to approve such investment.
NEW YORK, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Cellectis (NASDAQ:CLLS) today anounced that, following the consultation of its works council, it has now signed a binding Subsequent Investment Agreement with AstraZeneca (NASDAQ:AZN) regarding the contemplated additional equity investment of $140M by AstraZeneca, which was previously announced on November 1, 2023. The additional investment will be made by way of subscription of 10,000,000 "class A" convertible preferred shares and 18,000,000 "class B" convertible preferred shares, in each case at a price of $5.00 per share (the "Additional Investment").
The closing of the Additional Investment remains subject to (i) the approval of the extraordinary general meeting of the shareholders of Cellectis to be called in the coming days and expected to be held on or around December 22, 2023, (ii) clearance of such investment from the French Ministry of Economy according to the foreign direct investment French regulations, and (iii) other customary closing conditions. Immediately following the Additional Investment, it is anticipated that AstraZeneca would own ...